AXSOME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.71 USD | +1.31% |
|
-2.82% | -12.41% |
Financials (USD)
| Sales 2024 * | 379M | Sales 2025 * | 680M | Capitalization | 3.26B |
|---|---|---|---|---|---|
| Net income 2024 * | -180M | Net income 2025 * | 49M | EV / Sales 2024 * | 8.39 x |
| Net cash position 2024 * | 77.32M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 4.6 x |
| P/E ratio 2024 * |
-18.3
x | P/E ratio 2025 * |
74.3
x | Employees | 545 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Axsome Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +1.31% | ||
| 1 week | -2.82% | ||
| Current month | -12.64% | ||
| 1 month | -3.90% | ||
| 3 months | -17.50% | ||
| 6 months | +7.16% | ||
| Current year | -12.41% |
1 week
66.93
72.28
1 month
66.9383.89
Current year
66.9398.40
1 year
55.0298.40
3 years
19.3898.40
5 years
13.64109.94
10 years
1.94109.94
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 12-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 49 | 18-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 40 | 14-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Saad
BRD | Director/Board Member | 54 | 14-11-30 |
Susan Mahony
BRD | Director/Board Member | 60 | 23-10-10 |
Roger Jeffs
BRD | Director/Board Member | 62 | 14-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.26% | 0 M€ | 0.00% | - | |
| 0.14% | 237 M€ | +0.01% | - | |
| 0.14% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 68.81 | +0.88% | 467,399 |
| 24-04-15 | 68.21 | -1.36% | 430,813 |
| 24-04-12 | 69.15 | -3.60% | 594,653 |
| 24-04-11 | 71.73 | +1.07% | 782,192 |
| 24-04-10 | 70.97 | -2.30% | 571,892 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
68.81
USD
Average target price
121.1
USD
Spread / Average Target
+76.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.41% | 3.26B | |
| -4.89% | 85.08B | |
| +2.11% | 40.14B | |
| -25.74% | 28.37B | |
| +51.96% | 24.07B | |
| -6.17% | 17.24B | |
| -31.09% | 13.85B | |
| -6.58% | 12.29B | |
| -16.04% | 11.95B | |
| -4.19% | 8.02B |
- Stock Market
- Equities
- AXSM Stock
